BioXcel Therapeutics Inc (BTAI) - Net Assets
Based on the latest financial reports, BioXcel Therapeutics Inc (BTAI) has net assets worth $-105.54 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.02 Million) and total liabilities ($139.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BTAI intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-105.54 Million |
| % of Total Assets | -310.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | -143.07% |
| 10-Year Change | N/A |
| Growth Volatility | 299.79 |
BioXcel Therapeutics Inc - Net Assets Trend (2015–2025)
This chart illustrates how BioXcel Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See how many days can BioXcel Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BioXcel Therapeutics Inc (2015–2025)
The table below shows the annual net assets of BioXcel Therapeutics Inc from 2015 to 2025. For live valuation and market cap data, see BTAI market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-95.46 Million | -2.54% |
| 2024-12-31 | $-93.10 Million | -64.76% |
| 2023-12-31 | $-56.51 Million | -173.60% |
| 2022-12-31 | $76.78 Million | -65.36% |
| 2021-12-31 | $221.67 Million | +7.24% |
| 2020-12-31 | $206.70 Million | +668.53% |
| 2019-12-31 | $26.89 Million | -30.84% |
| 2018-12-31 | $38.89 Million | +4060.18% |
| 2017-12-31 | $-982.00K | -203.09% |
| 2016-12-31 | $-324.00K | -87.28% |
| 2015-12-31 | $-173.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioXcel Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72009400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $76.00K | % |
| Other Components | $624.55 Million | % |
| Total Equity | $-95.46 Million | 100.00% |
BioXcel Therapeutics Inc Competitors by Market Cap
The table below lists competitors of BioXcel Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ledtech Electronics Corp
TW:6164
|
$34.28 Million |
|
Sprintex Ltd
AU:SIX
|
$34.28 Million |
|
Accuray Incorporated
NASDAQ:ARAY
|
$34.30 Million |
|
FreeMs Corporation
KQ:053160
|
$34.32 Million |
|
Bicicletas Monark S.A
SA:BMKS3
|
$34.26 Million |
|
Arizona Lithium Ltd
AU:AZL
|
$34.26 Million |
|
Taylor Wimpey PLC
LSE:TW
|
$34.25 Million |
|
Barfresh Food Group Inc
NASDAQ:BRFH
|
$34.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioXcel Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -93,101,000 to -95,463,000, a change of -2,362,000.
- Net loss of 69,897,000 reduced equity.
- New share issuances of 58,142,000 increased equity.
- Other factors increased equity by 9,393,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-69.90 Million | -73.22% |
| Share Issuances | $58.14 Million | +60.91% |
| Other Changes | $9.39 Million | +9.84% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BioXcel Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-0.17 | $1.19 | x |
| 2016-12-31 | $-0.31 | $1.19 | x |
| 2017-12-31 | $-0.95 | $1.19 | x |
| 2018-12-31 | $42.70 | $1.19 | x |
| 2019-12-31 | $26.42 | $1.19 | x |
| 2020-12-31 | $152.52 | $1.19 | x |
| 2021-12-31 | $134.48 | $1.19 | x |
| 2022-12-31 | $43.85 | $1.19 | x |
| 2023-12-31 | $-31.04 | $1.19 | x |
| 2024-12-31 | $-36.73 | $1.19 | x |
| 2025-12-31 | $-7.82 | $1.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioXcel Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10887.38%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-43.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-618.70K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.09 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.44 Million |
| 2018 | -49.55% | 0.00% | 0.00x | 1.12x | $-23.16 Million |
| 2019 | -120.23% | 0.00% | 0.00x | 1.35x | $-35.02 Million |
| 2020 | -39.68% | -337481481.48% | 0.00x | 1.06x | $-102.68 Million |
| 2021 | -48.10% | 0.00% | 0.00x | 1.08x | $-128.80 Million |
| 2022 | -215.90% | -44201.87% | 0.00x | 2.68x | $-173.43 Million |
| 2023 | 0.00% | -12974.86% | 0.02x | 0.00x | $-173.40 Million |
| 2024 | 0.00% | -2630.14% | 0.06x | 0.00x | $-50.29 Million |
| 2025 | 0.00% | -10887.38% | 0.01x | 0.00x | $-60.35 Million |
Industry Comparison
This section compares BioXcel Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $379,169,986
- Average return on equity (ROE) among peers: -14.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioXcel Therapeutics Inc (BTAI) | $-105.54 Million | 0.00% | N/A | $34.27 Million |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $172.65 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $7.56 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $273.24 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $7.42 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $5.19 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $37.89 Million | 15.55% | 0.65x | $189.34 Million |
| ANI Pharmaceuticals Inc (ANIP) | $197.26 Million | 7.85% | 1.18x | $1.80 Billion |
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. I… Read more